Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

HER2 classification relies on immunohistochemistry ... HER2 assays are semiquantitative and were optimized to detect HER2 overexpression. Furthermore, some data suggest that IHC 0 cancers respond ...

1 Human epidermal growth factor receptor 2 (HER2/ErbB2) overexpression, the most studied member of the type I receptor tyrosine kinase family, is present in up to 25% of women with breast cancer ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

“From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...

In this context it has been suggested that hormone-receptor positive tumors with HER2 overexpression respond better to chemotherapy than tumors without HER2 overexpression. Interestingly ...

"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...